Amsterdam Molecular Therapeutics BV receives global rights to develop and commercialize AMT-020 for acute intermittent porphyria
Rights from University of Navarra, Pamplona, Spain strengthen AMT's portfolio of gene therapy products
02-Mar-2007 -
Amsterdam Molecular Therapeutics BV (AMT) announced that it has obtained exclusive worldwide rights to develop and commercialise AMT-020 as a therapeutic product from UTE CIMA, Proyecto de Biomedicina CIMA, S.L. and Digna Biotech (all parties part of the University of Navarra, Pamplona, ...
acute intermittent porphyria
Amsterdam Molecular Therapeutics
gene therapy
+2